Logo

Specific Diagnostics: Scott Wehage

Apr 15, 2021

Specific Diagnostics has appointed Scott Wehage the company's director of US clinical trials. He was previously clinical project manager for Becton Dickinson's global clinical development department and oversaw clinical trials for device and in vitro diagnostic product development. Prior to that, he was a program manager at Johns Hopkins University. Based in Mountain View, California, Specific Dx has developed an IVD system leveraging a metabolomic signature technology that allows for the detection and identification of microorganisms as they grow in culture. The first commercial application of the technology will be for the determination of antibiotic susceptibility.

Breaking News
The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.